<DOC>
	<DOCNO>NCT00862823</DOCNO>
	<brief_summary>The primary objective study determine average bioequivalence tenofovir , emtricitabine efavirenz extemporaneously prepared oral liquid formulation ( test formulation ) compare commercially available tablet formulation ( reference formulation ) . The study design open-label , randomize , 2-period , 2-treatment , 2-sequence , single-dose intensive pharmacokinetic study conduct healthy volunteer . Subjects randomize receive Atripla tablet ( reference formulation ) Atripla tablet crush mixed OraSweet solution ( test formulation ) Study Day 1 . Subjects undergo 12-hour intensive pharmacokinetic evaluation ingest single dose either test reference formulation . On day 2 3 , subject provide additional pharmacokinetic sample 24 48 hour post dose , respectively . Subjects complete washout period day 2 day 14 study drug ingest . On day 14 , subject ingest either reference test formulation ( opposite formulation receive Study Day 1 ) . All subject undergo another 12-hour intensive pharmacokinetic evaluation . On day 16 17 subject provide additional pharmacokinetic sample 24 48 hour post dose , respectively . Adverse event concomitant medication document throughout study . The sample size 16 base upon 10 % drop-out rate ( i.e . due lose follow-up , treatment discontinuation , etc. ) . Since investigator expect two subject complete study , investigator expect 14 evaluable subject . If discontinuation rate great 10 % , investigator continue enroll investigator get 14 evaluable subject . The primary endpoint determine average bioequivalence test reference formulation tenofovir , emtricitabine efavirenz accord FDA guidance bioequivalence test . The ratio test reference formulation mean Cmax AUC24 drug 90 % confidence interval around mean ratio determine . Average bioequivalence meet 90 % confidence interval around Cmax , AUC24 mean ratio drug fall within FDA 's predefined limit 0.80 1.25 .</brief_summary>
	<brief_title>The Bioequivalence Atripla Oral Liquid Formulation Compared With Tablet Formulation Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Efavirenz , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>Age ≥19 ≤65 , HIV1 negative , Able give consent , Nonsmoking , Screening EKG within normal limit , Females childbearing potential must negative pregnancy test screen agree use doublebarrier method contraception throughout study period . Subjects receive prescription overthecounter product exclude study . Subjects use form recreational drug exclude . Subjects follow laboratory abnormality within 30 day study entry exclude : SGOT ( AST ) /SGPT ( ALT ) &gt; 3 x upper limit normal ( ULN ) ( Subjects liver disease allow enroll unless AST/ALT level great three time ULN ) Bilirubin &gt; 2.5 x ULN Amylase &gt; 2 x ULN Absolute Neutrophil Count &lt; 1000 x 103/L Hgb &lt; 9.0 g/dl Platelets &lt; 50,000 cells/mm3 Serum Creatinine &gt; 2.5 mg/dl</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Healthy Volunteers</keyword>
</DOC>